A 48 Week Phase II, Randomized, Open-Label, Multicenter, Study to Evaluate the Efficacy and Safety of Two (2) EYS606 (pEYS606 administered by injection and electrotransfer to the ciliary muscle) Treatment Regimens in Patients with CNIU

Administered By

Awarded By

Contributors

Start/End

  • September 18, 2019 - December 31, 2021